CN102144979A - 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 - Google Patents
用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 Download PDFInfo
- Publication number
- CN102144979A CN102144979A CN 201110051372 CN201110051372A CN102144979A CN 102144979 A CN102144979 A CN 102144979A CN 201110051372 CN201110051372 CN 201110051372 CN 201110051372 A CN201110051372 A CN 201110051372A CN 102144979 A CN102144979 A CN 102144979A
- Authority
- CN
- China
- Prior art keywords
- gossypol
- acetate
- levorotation gossypol
- freeze
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229950005277 gossypol Drugs 0.000 title claims abstract description 105
- 238000002360 preparation method Methods 0.000 title claims abstract description 89
- 239000000843 powder Substances 0.000 title claims abstract description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 31
- 238000002347 injection Methods 0.000 title claims abstract description 28
- 239000007924 injection Substances 0.000 title claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000008215 water for injection Substances 0.000 claims abstract description 34
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 26
- 239000002904 solvent Substances 0.000 claims abstract description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 16
- 229930195725 Mannitol Natural products 0.000 claims abstract description 16
- 239000000594 mannitol Substances 0.000 claims abstract description 16
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- 229920001503 Glucan Polymers 0.000 claims abstract description 12
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims abstract description 12
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 193
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims description 95
- 229930000755 gossypol Natural products 0.000 claims description 95
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 68
- NIOHNDKHQHVLKA-UHFFFAOYSA-N acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound CC(O)=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 NIOHNDKHQHVLKA-UHFFFAOYSA-N 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 53
- 238000001035 drying Methods 0.000 claims description 35
- 238000010792 warming Methods 0.000 claims description 28
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 12
- 239000012982 microporous membrane Substances 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 11
- 238000011068 loading method Methods 0.000 abstract description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100513723A CN102144979B (zh) | 2011-03-03 | 2011-03-03 | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100513723A CN102144979B (zh) | 2011-03-03 | 2011-03-03 | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102144979A true CN102144979A (zh) | 2011-08-10 |
CN102144979B CN102144979B (zh) | 2012-05-23 |
Family
ID=44419584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100513723A Active CN102144979B (zh) | 2011-03-03 | 2011-03-03 | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102144979B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143853A (zh) * | 2021-03-30 | 2021-07-23 | 赜誉(上海)生物科技有限公司 | 一种高效型棉多酚类中药提取物水溶液制剂的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557295A (zh) * | 2004-02-02 | 2004-12-29 | 陕西盘龙制药集团有限公司 | 一种治疗妇科疾病的药剂 |
CN1827117A (zh) * | 2005-12-31 | 2006-09-06 | 西安北方药业有限公司 | 复方醋酸棉酚缓释药剂 |
CN101327201A (zh) * | 2007-06-20 | 2008-12-24 | 上海市计划生育科学研究所 | 棉酚或其类似物的液体制剂及其制备方法和用途 |
-
2011
- 2011-03-03 CN CN2011100513723A patent/CN102144979B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557295A (zh) * | 2004-02-02 | 2004-12-29 | 陕西盘龙制药集团有限公司 | 一种治疗妇科疾病的药剂 |
CN1827117A (zh) * | 2005-12-31 | 2006-09-06 | 西安北方药业有限公司 | 复方醋酸棉酚缓释药剂 |
CN101327201A (zh) * | 2007-06-20 | 2008-12-24 | 上海市计划生育科学研究所 | 棉酚或其类似物的液体制剂及其制备方法和用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143853A (zh) * | 2021-03-30 | 2021-07-23 | 赜誉(上海)生物科技有限公司 | 一种高效型棉多酚类中药提取物水溶液制剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102144979B (zh) | 2012-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO169155B (no) | Fremgangsmaate for fremstilling av ibuprofenholdige kapsler av myk gelatin | |
JP7079030B2 (ja) | ペメトレキセドを含む経口用医薬組成物及びその製造方法 | |
US11351184B2 (en) | Preparation of Pulsatilla saponin B4 for injection | |
CN105078905B (zh) | 一种注射用盐酸多西环素冻干粉针剂的制备方法 | |
US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
CN102525954B (zh) | 左旋棉酚及其醋酸盐的注射用冻干乳制剂 | |
CN102813632A (zh) | 一种稳定的胸腺法新制剂及其制备方法 | |
CN101108872B (zh) | 植物生物碱提取物及其制剂与用途 | |
CN102144979B (zh) | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 | |
KR100312622B1 (ko) | 생약을주성분으로한안정화된항암제조성물및그제조방법 | |
CN104688676A (zh) | 穿心莲内酯浓缩型液体组方及其医药用途 | |
RU2494733C1 (ru) | Фармацевтическая композиция на основе фитонутриентов с повышенной биодоступностью, обладающая противоопухолевой активностью, и способ ее получения (варианты) | |
CN106551915B (zh) | 肠溶组合物及其制备方法 | |
CN112972404A (zh) | 一种西地那非冻干口腔崩解片及其制备方法 | |
CN102138916B (zh) | 用于治疗肿瘤的左旋棉酚或其醋酸盐的环糊精包合物 | |
CN1762341B (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 | |
CN102716089A (zh) | 一种盐酸吉西他滨脂质体注射剂 | |
CN102488650A (zh) | 一种环磷腺苷药物组合物及其制备方法 | |
CN104274412A (zh) | 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂 | |
CN111465389B (zh) | 多西他赛共缀物的药物组合物及制备方法 | |
CN103565779A (zh) | 氧化苦参碱生物粘附缓释制剂及其制备方法 | |
CN101554370A (zh) | 注射用紫丁香苷、制备方法及应用 | |
CN104511022A (zh) | 一种紫杉醇的药物组合物 | |
CN103520186A (zh) | 一种注射用脂溶性维生素的药物组合物及其制备方法 | |
CN107536810B (zh) | 注射用(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺无菌粉末 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200113 Address after: 271100 building 12, pharmaceutical industrial park, Kouzhen, Laiwu District, Jinan City, Shandong Province Patentee after: Shandong peptide Biological Pharmaceutical Co.,Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 University Science and Technology Park B District A502 Patentee before: Shandong Hongli Lab Animal Experiment Research Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231130 Address after: 274100 Central Business District, Changjiang East Road, Luxi New District, Heze City, Shandong Province 266, Modern Pharmaceutical Port Patentee after: Dahe Pharmaceutical Technology (Shandong) Co.,Ltd. Address before: Building 12, Pharmaceutical Industry Park, Kouzhen, Laiwu District, Jinan City, Shandong Province, 271100 Patentee before: Shandong peptide Biological Pharmaceutical Co.,Ltd. |